Among patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor had failed, the risk of progression or death was significantly lower among those who received elotuzumab plus pomalidomide and dexamethasone than among those who received pomalidomide plus dexamethasone alone. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-3 ClinicalTrials.gov number, NCT02654132 .).
Sagar Lonial, Meletios A Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Philippe Moreau, María‐Victoria Mateos, Hila Magen, Andrew R. Belch, Donna Reece, Meral Beksaç, Andrew Spencer, Heather Oakervee, Robert Z. Orlowski, Masafumi Taniwaki, Christoph Röllig, Hermann Einsele, Ka Lung Wu, Anil Singhal, Jesús F. San Miguel, Morio Matsumoto, Jessica Katz, Eric Bleickardt, Valerie Poulart, Kenneth C. Anderson, Paul G. Richardson
Katja Weisel, Meletios A Dimopoulos, Jesús F. San Miguel, Agne Paner, Monika Engelhardt, Fiona Taylor, Jennifer Lord‐Bessen, Christine Yip, Mike Greenwood, Jackson Tang, Michèle Cavo
Meletios A Dimopoulos, K. Weisel, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Philippe Moreau, A. Baños, Albert Oriol, L. Garderet, Michèle Cavo, V. L. Ivanova, Adrían Alegre, Joaquín Martínez‐López, Christopher Chen, Andrew Spencer, Stefan Knop, Nizar J. Bahlis, Christoph Renner, Xin Yu, Kevin Hong, Lars Sternås,
Meletios A Dimopoulos, Andrew Spencer, Michael Attal, H. Miles Prince, Jean‐Luc Harousseau, Anna Dmoszyńska, Jesús F. San Miguel, Andrzej Hellmann, Thierry Façon, Robin Foà, Alessandro Corso, Zvenyslava Masliak, Marta Olesnyckyj, Zhinuan Yu, John Patin, Jerome B. Zeldis, Robert Knight
Discussion(0)
No comments yet. Be the first to comment.